{
  "drug_name": "Ertapenem",
  "tradename": "Invanz",
  "usage_and_dosing": {
    "general": [
      "Ertapenem is a carbapenem with a broad spectrum of activity against aerobic and anaerobic gram-negative bacilli. Unlike the other carbapenems, ertapenem has no activity against P. aeruginosa.",
      "Of the licensed carbapenems, ertapenem is the most susceptible to carbapenemases produced by Klebsiella species and other aerobic gram-negative bacilli.",
      "FDA-approved for treatment of community-acquired pneumonia, complicated urinary tract infections, pelvic infections, skin/skin structure infections and prophylaxis for colorectal surgery.",
      "An alternative antibiotic for Antibacterial Drug Resistant Genotypes.",
      "Can be given IM or IV. Lidocaine is diluent for ertapenem IM use; ask about lidocaine allergy."
    ],
    "adult_dose": {
      "usual_dose": "1 gm IV/IM q24h"
    },
    "pediatric_dose": {
      "dose_age_gt_28_days": "30 mg/kg/day (divided q12h)",
      "max_day": "1 gm"
    }
  },
  "renal_adjustment": {
    "half_life_normal": "4",
    "half_life_esrd": ">4",
    "dose_renal_function_normal": "1 gm IV q24h",
    "crcl_or_egfr": "CrCl >30 mL/min/1.73 m²: No dosage adjustment. CrCl ≤30 mL/min/1.73 m²: 500 mg q24h",
    "hemodialysis": "500 mg q24h (+150 mg AD if given ≤6 hr bef HD), OR 500 mg 3x/wk AD 6",
    "capd": "500 mg q24h",
    "crrt": "0.5-1 gm q24h",
    "sled": "1 gm q24h 32"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No dosage adjustment",
    "severe_impairment_child_pugh_c": "No dosage adjustment"
  },
  "other_adjustment": [
    "ECMO: See ECMO Drug Dosing Adjustment.",
    "Obesity: See Obesity Dosing Adjustments."
  ],
  "adverse_effects": [
    "GI: nausea/vomiting (3%), diarrhea (6%).",
    "Increased LFTs (6%).",
    "Headache (2%).",
    "Hypersensitivity reactions: fever, rash, anaphylaxis. Reports of DRESS. For cross-allergenicity, see Carbapenems, Overview and Drug Allergy: Penicillins, Cephalosporins, Overview.",
    "Positive Coombs (1%), neutropenia, eosinophilia.",
    "Muscle weakness described.",
    "Local phlebitis (4%). Hypersensitivity reaction to the lidocaine diluent is possible.",
    "Neurotoxicity (e.g., seizures), especially in patients with renal impairment or predisposing conditions. Good review of 125 cases: Open Forum Infect Dis 2024;11(5):ofae214.",
    "Visual hallucinations reported (N Zealand Med J 122:76, 2009)."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "Human data insufficient; nontoxic in animals. Considered safe for use in pregnant patients.",
    "lactation": "Safe, monitor infant for GI toxicity",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {
    "preferred": [
      "Bacteroides fragilis",
      "E. coli, extended spectrum beta lactamase producer (ESBL)",
      "Providencia sp."
    ],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "T>MIC",
    "preparations": "Injection",
    "food_recommendation": null,
    "oral_absorption_percent": null,
    "tmax_hr": null,
    "peak_serum_conc_ug_ml": "154 (1 gm IV, SD)",
    "peak_urine_conc_ug_ml": "No data",
    "protein_binding_percent": "95",
    "volume_of_distribution_vd_l_kg_vss": "0.12 L/kg (Vss)",
    "avg_serum_half_life_hr": "4",
    "elimination": "Renal",
    "bile_penetration_percent": "10",
    "csf_blood_percent": "No data",
    "therapeutic_levels_in_csf": "No data",
    "auc_ug_hr_ml": "572.1 (1 gm IV, 0-inf)"
  },
  "enzyme_transporter_mediated_interactions": {
      "cyp450s_substrate": [],
      "transporters_substrate": ["OAT1", "OAT3"],
      "ugts_substrate": [],
      "cyp450s_inhibited": [],
      "transporters_inhibited": [],
      "ugts_inhibited": [],
      "cyp450s_induced": [],
      "transporters_induced": [],
      "ugts_induced": [],
      "impact_on_serum_drug_concentrations": "None expected"
  },
  "major_drug_interactions": [
      {
          "drug": "Probenecid",
          "effect": "↑ ertapenem",
          "management": "Monitor, adjust dosage"
      },
      {
          "drug": "Valproic acid",
          "effect": "↓ valproic acid",
          "management": "Avoid co-administration"
      }
  ]
}
